Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant African swine fever virus Protein MGF 505-9R (Mal-040), partial CSB-YP315929AYE
CSB-EP315929AYE
CSB-BP315929AYE
CSB-MP315929AYE
CSB-EP315929AYE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Protein MGF 505-11L (Pret-162), partial CSB-YP315930AYG
CSB-EP315930AYG
CSB-BP315930AYG
CSB-MP315930AYG
CSB-EP315930AYG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus CD2 homolog (Pret-070), partial CSB-YP315931AYG
CSB-EP315931AYG
CSB-BP315931AYG
CSB-MP315931AYG
CSB-EP315931AYG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Putative helicase C962R (Pret-083), partial CSB-YP315932AYG
CSB-EP315932AYG
CSB-BP315932AYG
CSB-MP315932AYG
CSB-EP315932AYG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Structural DNA-binding protein p10 (Pret-061) CSB-YP315933AYG
CSB-EP315933AYG
CSB-BP315933AYG
CSB-MP315933AYG
CSB-EP315933AYG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Major structural protein p17 (Pret-119), partial CSB-YP315934AYG1
CSB-EP315934AYG1
CSB-BP315934AYG1
CSB-MP315934AYG1
CSB-EP315934AYG1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Structural protein p49 (Pret-087) CSB-YP315935AYG
CSB-EP315935AYG
CSB-BP315935AYG
CSB-MP315935AYG
CSB-EP315935AYG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Polyprotein pp62 (Mal-102), partial CSB-YP315936AYE
CSB-EP315936AYE
CSB-BP315936AYE
CSB-MP315936AYE
CSB-EP315936AYE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein C122R (Mal-073) CSB-YP315937AYE
CSB-EP315937AYE
CSB-BP315937AYE
CSB-MP315937AYE
CSB-EP315937AYE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein H124R (Pret-127) CSB-YP315938AYG
CSB-EP315938AYG
CSB-BP315938AYG
CSB-MP315938AYG
CSB-EP315938AYG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein C129R (Mal-070) CSB-YP315939AYE
CSB-EP315939AYE
CSB-BP315939AYE
CSB-MP315939AYE
CSB-EP315939AYE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Structural protein A137R (War-052) CSB-YP315940AEI
CSB-EP315940AEI
CSB-BP315940AEI
CSB-MP315940AEI
CSB-EP315940AEI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein E146L (War-139), partial CSB-YP315941AEI
CSB-EP315941AEI
CSB-BP315941AEI
CSB-MP315941AEI
CSB-EP315941AEI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Lectin-like protein EP153R (Mal-065), partial CSB-YP315942AYE
CSB-EP315942AYE
CSB-BP315942AYE
CSB-MP315942AYE
CSB-EP315942AYE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Transmembrane protein B169L (Pret-088), partial CSB-YP315943AYG1
CSB-EP315943AYG1
CSB-BP315943AYG1
CSB-MP315943AYG1
CSB-EP315943AYG1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein B175L (War-095) CSB-YP315944AEI
CSB-EP315944AEI
CSB-BP315944AEI
CSB-MP315944AEI
CSB-EP315944AEI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Late protein I196L (Mal-153) CSB-YP315945AYE
CSB-EP315945AYE
CSB-BP315945AYE
CSB-MP315945AYE
CSB-EP315945AYE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein K205R (Ken-060) CSB-YP315946AEB
CSB-EP315946AEB
CSB-BP315946AEB
CSB-MP315946AEB
CSB-EP315946AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein H233R (Ken-130) CSB-YP315947AEB
CSB-EP315947AEB
CSB-BP315947AEB
CSB-MP315947AEB
CSB-EP315947AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein B263R (Ken-098) CSB-YP315948AEB
CSB-EP315948AEB
CSB-BP315948AEB
CSB-MP315948AEB
CSB-EP315948AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>